Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | IGF1R | P08069 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675253 | 0.84 | MEN1 (0.62) | MEN1KMT2AIGF1RCDK1CDK2 | |
| SCHEMBL30394357 | 0.83 | AURKA (0.51) | MEN1KMT2ACDK2PIN1NPC1 | |
| SCHEMBL29019918 | 0.83 | AURKA (0.51) | MEN1KMT2ACDK2PIN1NPC1 | |
| SCHEMBL12277575 | 0.83 | AURKA (0.51) | MEN1KMT2APIN1NPC1AURKA | |
| SCHEMBL1774193 | 0.83 | IGF1R (0.68) | MEN1KMT2AIGF1RCDK1CDK2 | |
| SCHEMBL22719010 | 0.83 | MEN1 (0.61) | MEN1KMT2AIGF1RNPC1AURKA | |
| SCHEMBL29535612 | 0.83 | MEN1 (0.61) | MEN1KMT2AIGF1RNPC1AURKA | |
| SCHEMBL9945496 | 0.82 | EGFR (0.61) | MEN1KMT2AIGF1RCDK1AURKA | |
| SCHEMBL16264851 | 0.81 | MEN1 (0.45) | MEN1KMT2APIN1NPC1AURKA | |
| SCHEMBL15741405 | 0.81 | AURKA (0.61) | MEN1KMT2AIGF1RCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | MEN1 365/4885KMT2A 2928/4885IGF1R 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.